Literature DB >> 2522716

Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty.

S G Ellis1, G S Roubin, J Wilentz, J S Douglas, S B King.   

Abstract

Smooth muscle cell proliferation induced by intimal denudation similar to that produced by coronary angioplasty has been decreased by early and brief heparin administration in animal models. Heparin might also decrease the incidence of thrombus-induced postdenudation arterial obstruction, albiet at risk of bleeding. To evaluate the risks and benefits of heparin after coronary angioplasty, 416 patients (469 vessel sites) with successful coronary angioplasty without large dissection were randomized to heparin (titrated to partial thromboplastin time 1.5 to 2.5 times normal) or dextrose administered for 18 to 24 hours. Patients also had received heparin during angioplasty (usually 10,000 to 15,000 units), and they received aspirin for a period of 6 months. Heparin and dextrose groups were not different in the percentage of patients with male sex (74% in the heparin group and 75% in the dextrose group, p = NS), postangioplasty tear or dissection (30% in the heparin group and 30% in the dextrose group, p = NS), or postangioplasty percent stenosis greater than 35% (31% in the heparin group and 30% in the dextrose group, p = NS). Partial thromboplastin time during treatment in the heparin group was 56 +/- 22 seconds and in the dextrose group 27 +/- 9 seconds (p less than 0.001). Late angiographic follow-up (180 +/- 81 days) was achieved in 58.4% in the heparin group and 64.5% in the control group. Of patients with late angiographic follow-up, 41.2% and 36.7% randomized to heparin and dextrose, respectively, had documented restenosis (greater than or equal to 50% diameter stenosis at one or more the sites dilated) (p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522716     DOI: 10.1016/0002-8703(89)90612-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  22 in total

1.  The Heparin Rebound Phenomenon-Does It Offer Insights Toward Understanding the Pathobiology of Coronary Thrombosis and Its Treatment?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Antithrombotic Therapy during Percutaneous Coronary Intervention.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 3.  Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

4.  Safety of low dose heparin in elective coronary angioplasty.

Authors:  K T Koch; J J Piek; R J de Winter; G K David; K Mulder; J G Tijssen; K I Lie
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 5.  Cardiology.

Authors:  L D Smith; D J Coltart
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

Review 6.  A systematic review of Cochrane anticoagulation reviews.

Authors:  David Keith Cundiff
Journal:  Medscape J Med       Date:  2009-01-06

Review 7.  Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II).

Authors:  J P Herrman; W R Hermans; J Vos; P W Serruys
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 8.  Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.

Authors:  M Verstraete
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 9.  Coronary restenosis and gene therapy.

Authors:  W Mazur; N M Ali; A E Raizner; B A French
Journal:  Tex Heart Inst J       Date:  1994

10.  Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.

Authors:  M W Chang; E Barr; M M Lu; K Barton; J M Leiden
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.